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Structural mechanisms of DREAM
complex assembly and regulation
Keelan Z. Guiley,1 Tyler J. Liban,1 Jessica G. Felthousen,2,3 Parameshwaran Ramanan,1
Larisa Litovchick,2,3 and Seth M. Rubin1
1Department of Chemistry and Biochemistry, University of California at Santa Cruz, Santa Cruz, California 95064, USA;
2Division of Hematology, Oncology, and Palliative Care, 3Massey Cancer Center, Virginia Commonwealth University,
Richmond, Virginia 23298, USA
The DREAM complex represses cell cycle genes during quiescence through scaffolding MuvB proteins with E2F4/5
and the Rb tumor suppressor paralog p107 or p130. Upon cell cycle entry, MuvB dissociates from p107/p130 and
recruits B-Myb and FoxM1 for up-regulating mitotic gene expression. To understand the biochemical mechanisms
underpinning DREAM function and regulation, we investigated the structural basis for DREAM assembly. We
identified a sequence in the MuvB component LIN52 that binds directly to the pocket domains of p107 and p130
when phosphorylated on the DYRK1A kinase site S28. A crystal structure of the LIN52–p107 complex reveals that
LIN52 uses a suboptimal LxSxExL sequence togetherwith the phosphate at nearby S28 to bind the LxCxE cleft of the
pocket domain with high affinity. The structure explains the specificity for p107/p130 over Rb in the DREAM
complex and how the complex is disrupted by viral oncoproteins. Based on insights from the structure, we addressed
how DREAM is disassembled upon cell cycle entry. We found that p130 and B-Myb can both bind the core MuvB
complex simultaneously but that cyclin-dependent kinase phosphorylation of p130 weakens its association. To-
gether, our data inform a novel target interface for studyingMuvB and p130 function and the design of inhibitors that
prevent tumor escape in quiescence.
[Keywords: cyclin-dependent kinases; DREAMcomplex;MuvB; cell cycle; phosphorylation; retinoblastoma-like proteins
p107 and p130]
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Cell cycle exit is a critical process for differentiation and
tumor prevention, and cancer cells often have lesions in
pathways that control temporary (quiescence) or per-
manent (senescence) exit. Understanding fundamental
mechanisms of cell cycle exit is critical for understanding
development and ultimately designing therapeutic strate-
gies that manipulate exit pathways for halting tumor pro-
liferation. Quiescence has recently been shown to be
dependent on the highly conserved protein complex
known as DREAM (Litovchick et al. 2007, 2011; Sadasi-
vam and DeCaprio 2013). Genetics experiments in model
organisms reveal an essential role for DREAM compo-
nents in differentiation, cell proliferation, and tumor sup-
pression (Korenjak et al. 2004; Lewis et al. 2004; Harrison
et al. 2006; Litovchick et al. 2007; van den Heuvel and
Dyson 2008; Reichert et al. 2010). DREAM-deficient
mice die shortly after birth with bone developmental de-
fects that result from aberrant chondrocyte differentiation
(Forristal et al. 2014). In human cell culture, DREAM is as-
sembled upon serum starvation in an experimental state
of quiescence, and disruption of the DREAM complex
drives cells back into the cell cycle despite environmental
cues to arrest (Pilkinton et al. 2007; Schmit et al. 2007;
Litovchick et al. 2011).
Chromatin immunoprecipitation (ChIP) has located
DREAM proteins at a majority of E2F and cell cycle ho-
mology region (CHR) promoters in human cells, and
gene expression analysis has implicated DREAM as a re-
pressor of cell cycle genes (Litovchick et al. 2007; Schmit
et al. 2007; Muller et al. 2012). The mechanism of how
DREAM regulates transcription has not been elucidated,
but it is clear that its central components scaffold a num-
ber of key cell cycle transcription factors, including E2F4/
5, B-Myb, FoxM1, and the Rb tumor suppressor family
paralogs p107 and p130 (Korenjak et al. 2004; Lewis
et al. 2004; Litovchick et al. 2007; Schmit et al. 2007; Sada-
sivam et al. 2012). DREAM was originally isolated
through biochemical purification in flies and worms,
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and in each case, the complex containedmultivulval class
B protein homologs LIN9, LIN37, LIN52, LIN54, and
RBAP48 (mammalian protein names), which together
are called theMuvB subcomplex (Korenjak et al. 2004; Le-
wis et al. 2004; Harrison et al. 2006; van den Heuvel and
Dyson 2008). The biochemical functions of these proteins
are unknown, with the exception of RBAP48 and LIN54,
which bind histones andDNA, respectively (van denHeu-
vel and Dyson 2008; Sadasivam and DeCaprio 2013).
Inmammaliancells,MuvBassociateswithp130–E2F4/5
to form DREAM in G0 and early G1 and associates with
B-MybduringSphase to formtheMyb–MuvB (MMB) com-
plex (Pilkinton et al. 2007; Schmit et al. 2007; Litovchick
et al. 2011; Sadasivam et al. 2012).While DREAM repress-
es gene expression, MMB activates late cell cycle genes
during S phase and G2 both with and without FoxM1
(Georlette et al. 2007; Litovchick et al. 2007; Pilkinton
et al. 2007; Schmit et al. 2007; Wen et al. 2008; Sadasivam
et al. 2012). MuvB thus has an intriguing role in unifying
cell cycle-dependent gene expression; however, themech-
anisms by which DREAM and MMB–FoxM1 are assem-
bled and regulated to carry out their specific functions
are not well understood. DREAM formation requires
the phosphorylation of MuvB protein LIN52 at serine res-
idue 28 (phosS28) by the DYRK1A kinase (Litovchick
et al. 2011).“DeltaDREAM”mice that lackp130andcarry
a p107 mutant allele incapable of binding MuvB dis-
play a phenotype identical to that of p107/p130 double-
knockout mice, suggesting an intimate relationship be-
tween the pocket proteins and MuvB proteins during cell
cycle arrest (Forristal et al. 2014). While there are some re-
ports of MuvB binding Rb (Gagrica et al. 2004; Korenjak
et al. 2004), other evidence indicates that the DREAM
complex only assembles with either p107 or p130 (Litov-
chick et al. 2007; Pilkinton et al. 2007; Schmit et al. 2007;
Forristal et al. 2014). p130 expression levels are highduring
quiescence, and p130 is an established biomarker at this
stage of the cell cycle in which DREAM is a repressor
of gene expression (Smith et al. 1996; Henley and Dick
2012). Loss of p130 results in up-regulated expression of
p107 and subsequent recruitment of p107 toMuvB (Litov-
chick et al. 2007; Forristal et al. 2014). MuvB dissociation
from pocket proteins coincides with cyclin-dependent
kinase (Cdk) activity (Pilkinton et al. 2007), suggesting
that Cdk phosphorylation of p107 and p130 may inhibit
DREAM formation in cycling cells. Knowledge of the
molecular architecture of the MuvB complex, howMuvB
binds different transcription factors, and how these associ-
ations aremanipulated throughout the cell cycle is impor-
tant for understanding fundamental processes such as
entry into quiescence and mitotic cell cycle control.
Here we describe the structural mechanisms of
DREAM assembly following DYRK1A phosphorylation
and DREAM inhibition by either oncogenic viral proteins
or Cdk phosphorylation. We found that phosphorylated
LIN52 binds the pocket domain of p107 or p130 using a
short sequence that is a tunable variation of the canonical
LxCxExL Rb-binding sequence. A crystal structure of a
LIN52–p107 complex explains the requirement for phos-
phorylation, why the association is specific for p107/
p130 and not Rb, and how DREAM is inhibited by viral
proteins. The structural observations lead us to uncover
a novel model for cell cycle-dependent regulation of
DREAMassembly inwhichCdk phosphorylation of pock-
et proteins induces a conformation that is incompatible
with LIN52 binding.
Results
p107 and p130 directly associate with LIN52
It has been shown previously that p107 and p130 coimmu-
noprecipitate with MuvB proteins if S28 in LIN52 is
phosphorylated by DYRK1A (Litovchick et al. 2011). To
determine whether LIN52 directly associates with p130,
we performed a series of binding experiments with re-
combinant, purified proteins. We first purified full-length
GST-LIN52-HIS and GST-p130, both expressed in Sf9
cells, and found coprecipitation using Ni2+ affinity resin
(Fig. 1A). Electrospray mass spectrometry indicated that
the LIN52 purified from Sf9 cells is phosphorylated (Sup-
plemental Fig. 1A,B). Given the observation that the bind-
ing appears substoichiometric, we postulated that p130 is
heterogeneously phosphorylated in Sf9 cells, as previously
observed for Rb (Burke et al. 2010), and that phosphoryla-
tion weakens LIN52 association. We treated p130 with λ
phosphatase during purification and observed a band shift
on a Phos-tag SDS-PAGE gel (Supplemental Fig. 1C). After
treatment with and subsequent separation from phospha-
tase, the p130–LIN52 complex stability appears increased
(Fig. 1A).
We next tested whether phosphorylation of S28 in
LIN52 is necessary for its direct interaction with pocket
proteins. p130 and p107 pocket domains were expressed
and purified from Escherichia coli without post-transla-
tional modifications. These constructs (p107ΔL and
p130ΔL) each lack two internal loops and are similar to
crystallized Rb constructs thatmaintain E2F and viral pro-
tein-binding activity (Lee et al. 1998; Balog et al. 2011).We
also purified LIN52 constructs expressed in Sf9 cells con-
taining the N-terminal domain (residues 13–45; LIN5213–
45). We found that LIN5213–45 is sufficient for direct asso-
ciation with the p130 and p107 pocket domains. An S28A
mutation in LIN5213–45 or λ phosphatase treatment reduc-
es binding to p130 and p107 (Fig. 1B,C), demonstrating the
importance of S28 phosphorylation for formation of the
complex.
The pocket domain contains two protein interaction in-
terfaces: the LxCxE cleft and the E2F transactivation
domain (E2FTD)-binding site (Lee et al. 1998, 2002; Xiao
et al. 2003; Dick and Rubin 2013). The LxCxE cleft binds
viral and endogenous proteins containing an LxCxExφ se-
quence motif (x is any amino acid, and φ is a hydrophobic
amino acid) (Jones et al. 1990; Lee et al. 1998; Singh et al.
2005). A p107 cleft mutant fails to assemble DREAM in
vivo (Forristal et al. 2014) and we therefore hypothesized
that LIN52 directly binds to the LxCxE cleft rather than
the E2FTD site. In support of this hypothesis, a purified
p107 pocket domain cleft mutant (I931A, N935A, and
V939A) fails to bind LIN52 (Fig. 1D).
Guiley et al.
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The DREAM complex is perturbed in cervical cancer
cells infected with human papillomavirus type 16
(HPV16), and knockdown of the oncoprotein HPV16 E7
rescues DREAM assembly and promotes cell cycle arrest
(Nor Rashid et al. 2011). To determine whether HPV16
E7 can inhibit the direct LIN52 association with the p130
pocket domain, we used a fluorescence polarization
(FP) competitionassay.ALIN5212–34;phosS28peptidewas la-
beled with a tetramethylrhodamine (TMR) dye andmixed
with increasing amounts of p130ΔL to obtain FP satura-
tioncurves.AdditionofE721–29 peptide to thebinding reac-
tion shifted the curves such that p130ΔL appeared to bind
with weaker affinity (Fig. 1E). We then quantified the E7
peptide inhibition (Ki = 170 ± 50 nM) by displacing labeled
LIN5212–34;phosS28 peptide in the FP assay (Fig. 1F). E721–29
contains an LxCxExL motif and inhibits LIN52 from in-
teracting with p130, indicating that E7 disrupts DREAM
by competitive inhibition at the LxCxE cleft of p130.
Figure 1. Direct association between LIN52 and p107/p130. Coprecipitation experiments performedwith recombinant purified proteins.
The indicated proteins were mixed and precipitated with the appropriate resin, and both unbound (U) and bound (B) fractions were ana-
lyzed using PAGE and Coomassie staining. (A) Coprecipitation of full-length GST-p130 and GST-LIN52-HIS expressed in Sf9 cells using
Ni2+-NTA resin. Treatment of the p130 with λ phosphatase during purification increases the amount of p130 appearing in the bound frac-
tion. (B) Coprecipitation of the untagged p130ΔL pocket domain expressed in Sf9 cells with GST-LIN5213–45 using GS4B sepharose resin.
Mutation of S28 in LIN52 or its treatment with λ phosphatase weakens the p130ΔL association. (C ) Same as B but with a p107ΔL pocket
domain. (D) An experiment similar to that in B but using a p107 pocket domain (loops intact) and an LxCxE cleft (I931A, N935A, and
V939A) mutant. (E) A fluorescence polarization (FP) assay demonstrating inhibition of the LIN52–p130 association by a human papillo-
mavirus (HPV) E7 peptide. Twenty nanomolar TMR-LIN5212–34;phosS28 was mixed with increasing concentrations of p130ΔL. Different
saturation curves are at the indicated molar ratio of TMR-LIN5212–34;phosS28 to E721–29 peptide. The affinity of TMR-LIN5212–34;phosS28
in the absence of E721–29 is Kd = 53 ± 2 nM. (F ) FP measurements made of 10 nM TMR-LIN52
12–34;phosS28 in the presence of saturating
(2000 nM) p130ΔL and increasing concentrations of E721–29 peptide (squares) as the inhibitor (I). As a negative control, a peptide corre-
sponding to the N terminus of Cyclin D1 (residues 1–17) was used (triangles). This peptide does not associate with p130ΔL (Supplemental
Fig. 5).
DREAM assembly and regulation
GENES & DEVELOPMENT 963
 Cold Spring Harbor Laboratory Press on December 7, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Crystal structures of LIN52–p107and E7–p107 complexes
To identify the molecular interactions involved in
DREAMassembly and oncoprotein-facilitated disruption,
we solved the crystal structures of the p107ΔL pocket
domain bound to a phosphorylated synthetic LIN52 pep-
tide (LIN5212–34;phosS28) at 2.3 Å and bound to an E7
(E721–29) peptide at 2.2 Å (Fig. 2; Table 1). The structures
reveal that the overall fold of the p107 pocket domain is
similar to that of Rb, consisting of two helical subdomains
called the A and B boxes. Each subdomain contains a five-
helix cyclin fold flanked by additional helices that form
the A–B interface or the LxCxE interface or cover hydro-
phobic surfaces. As with previous Rb pocket domain
structures (Lee et al. 1998, 2002; Xiao et al. 2003; Balog
et al. 2011), most residues in the central loop between
the two subdomains were left out of the crystallized con-
struct, and the residues that remain are not visible in the
electron density.
Structural alignment of the p107 and Rb pocket do-
mains (Protein Data Bank [PDB]: 3POM) shows a root
mean square deviation (RMSD) in the Cα position of
only 1.2 Å (Supplemental Fig. 2A). While most secondary
structural elements compare, relative to Rb, the p107
A-boxhastwoadditional smallhelices (α4′ andα10′).These
helices consist of sequences for which the corresponding
electron density in Rb was not observable. α10′ occurs at
theC terminus of theA-box and creates additional A–B in-
terface contacts through packing against α11. The E7 pep-
tide binds to the LxCxE cleft in the B-box of p107 as
previously observed in the Rb–E7 complex structure
(Fig. 2; Supplemental Fig. 2B; Lee et al. 1998). The similar
specific contacts made are consistent with the high se-
quence homology between Rb and p107within the LxCxE
cleft.
In the p107ΔL–LIN5212–34;phosS28 structure, LIN52
binds at the LxCxE cleft, consistent with our coprecipita-
tion experiments. The LIN52 peptide binds with an
LxSxExL (residues 18–24) motif and makes a set of inter-
actions similar to that of the E7 peptide (Figs. 2, 3A; Sup-
plemental Fig. 3). However, several striking differences
arise from the presence of the more polar hydroxyl group
in the LIN52 serine side chain. S20 occupies the place in
the sequence analogous to that of the cysteine in the ca-
nonical E7 peptide LxCxExφmotif. C24 in the E7 peptide
fits in a hydrophobic pocket formed by F861 and Y849.
In contrast, S20 in LIN52 makes hydrogen bonds with
the K853 and Y849 side chains. The positions of both
the F861 and Y849 side chains are changed in the LIN52
complex such that the F861 phenyl ring is flipped out to-
ward solvent. Whereas the E7 peptide E26 side chain
makes hydrogen bonds with the backbone of F861 and
Q862, the LIN52 E22 side chain is occluded from the anal-
ogous position by the flipped-out F861 side chain. These
structural differences suggest that the LIN52 serine-con-
taining motif binds with weaker affinity than the canoni-
cal E7 motif.
The S28 phosphoserine side chain in LIN52 binds a pos-
itively charged pocket in p107 consisting of R869, S876,
Y879, and R880 (Fig. 2). These p107 side chains are highly
conserved in p107 and p130 paralogs but not in Rb (Fig.
3A). Rb notably has F739 at the Y879 position in p107
and lacks the phenolic hydroxyl group that hydrogen-
bonds with the LIN52 phosphate. The lack of the phos-
phate-binding pocket inRb supports and explains previous
observations that theDREAMcomplex does not assemble
Figure 2. Crystal structures of the p107 pock-
et domain in complex with LIN5212–34;phosS28
and E721–29. (Insets, left) The LIN52 and E7
peptides both bind at the LxCxE cleft. (Inset,
top) The LIN52 association is mediated by
the S28 phosphate, which contacts a p107/
p130-specific binding pocket.
Guiley et al.
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with Rb (Litovchick et al. 2007; Pilkinton et al. 2007;
Schmit et al. 2007; Forristal et al. 2014). The intervening
amino acids between the LxSxExL sequence and phosS28
loop out from the p107 domain and do notmake any direct
contacts (Fig. 2). We also solved a crystal structure of
p107ΔL in complex with a mutant peptide (LIN5212–34;
P29A;phosS28) that binds with higher affinity (Tables 1, 2).
The electron density corresponding to the LIN52 peptide
is stronger in this structure and allows for observation of
additional interactions between W32 in LIN52 and E863,
M865, R869, and Y879 in p107 (Supplemental Fig. 3).
While p107 and p130 loss in genetic models does not
readily lead to tumors, there is evidence that p107 and
p130 have tumor suppression function and can compen-
sate for Rb loss in certain contexts (Dannenberg et al.
2004; Wirt and Sage 2010). The cBioPortal for Cancer Ge-
nomics catalogs a number of missense and nonsense mu-
tations in both p107 and p130 that occur in human cancer
samples (Gao et al. 2013). We found that 31 of the current-
ly reported missense mutations for p107 are within the
structured pocket domain (Supplemental Fig. 4). Based
on the location of these residues in our crystal structure,
we predict that 21 of these 31mutationswould destabilize
the protein and likely result in functional loss. Three oth-
er mutations map to the E2F-binding surface based on the
analogous Rb–E2F structure (Lee et al. 2002; Xiao et al.
2003). Notably, two mutations (R880I and Y934C) and
an analogous p130 mutation map to the LIN52 interface,
and we found that these p107 mutations weaken the
LIN5212–34;phosS28 peptide affinity (Supplemental Fig. 4).
These observations support the idea that p107/p130-de-
pendent growth control through both E2F inhibition and
DREAM function plays an important role in tumor
suppression.
LIN52 S28 phosphorylation increases
LxSxExL affinity
Our structural data suggest that the LxSxExL sequence in
LIN52 binds to the pocket domainwith lower affinity than
a canonical LxCxExL sequence and that phosphorylation
increases affinity specifically in p107 and p130 to make
a more stable complex. We tested these ideas by quantita-
tively measuring the affinity of different LIN52 peptides
using isothermal titration calorimetry (ITC) (Fig. 3B; Sup-
plemental Fig. 5). LIN5212–34;phosS28 binds p107ΔL with an
affinity of Kd = 1.4 μM±0.9 μM and p130ΔL with a similar
affinity of Kd = 1.0 μM±0.1 μM. An unphosphorylated
LIN5212–34 peptide binds p107ΔL with weaker affinity
(Kd = 5.9 μM±0.9 μM). Mutation of S20 to a cysteine
Table 1. X-ray crystallography data collection and refinement statistics for crystals containing p107ΔL and the indicated peptide
E721–29 LIN5212–34;phosS28 LIN5212–34;P29A; phosS28
Data collection
Space group C21 C2221 C2221
Cell dimensions
a, b, c 99.7, 76.6, 74.7 75.4, 101.1, 140.7 74.8, 100.5, 142.8
α, β, γ 90, 120.3, 90 90, 90, 90 90, 90, 90
Resolution 57.2 Å–2.2 Å 60.5 Å–2.3 Å 71.4 Å–2.4 Å
Total reflections 48,201 159,897 112,012
Unique reflections 21,552 24,252 21,397
I/σ 8.6 (2.1) 7.1 (2.2) 6.6 (1.8)
Completeness 93.2% (94.4%) 99.5% (97.9%) 99.3% (97.9%)
Redundancy 2.2 (2.2) 6.6 (6.4) 5.2 (5.4)
Rpim 5.8% (25.2%) 7.0% (39.2%) 8.3% (44.2%)
CC1/2 0.992 (0.759) 0.991 (0.556) 0.987 (0.472)
Refinement
Resolution 57.2 Å–2.2 Å 60.5 Å–2.3 Å 71.4 Å–2.4 Å
Number of reflections 21,552 (2171) 24,232 (2297) 21,369 (2084)
Rwork 18.4% (21.9%) 19.9% (27.4%) 19.5% (26.9%)
Rfree 24.0 (26.9%) 24.2% (30.0%) 24.2% (33.6%)
Number of atoms 3008 2970 3082
Protein 2877 2849 2934
Water 111 95 128
RMSDs
Bond lengths 0.005 0.005 0.007
Bond angles 0.87° 0.93° 1.23°
Average B factor
Overall 36.00 Å2 61.30 Å2 52.70 Å2
p107ΔL 34.53 Å2 59.10 Å2 50.25 Å2
Peptide 66.10 Å2 129.12 Å2 92.95 Å2
Ramachandran analysis
Favored 97.4% 96.0% 96.0%
Outliers 0.0% 0.3% 0.3%
Values in parenthesis are for the high-resolution shell.
DREAM assembly and regulation
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increases affinity for p107ΔL (LIN5212–34;S20C; Kd = 0.120
μM±0.007 μM). The sensitivity of the canonical LxCxExφ
motif to a serine substitution has been observed previous-
ly in the case of the E7 peptide and Rb (Jones et al. 1990).
We found that the LIN5212–34;S20C affinity for p107ΔL is
similar to the affinity of the HPV16 E721–29 peptide for
p107ΔL (Kd = 0.16 μM±0.04 μM). S28 phosphorylation
in the context of the S20C mutation still increases affin-
ity (LIN5212–34;S20C;phosS28; Kd = 0.021 μM±0.004 μM)
such that it is tighter than the wild-type phosphorylated
LIN52 sequence.
No binding was observable upon mixing of either the
LIN5212–34 or LIN5212–34;phosS28 peptide with Rb. The
LIN5212–34;S20C peptide (Kd = 0.3 μM±0.1 μM) binds Rb
withanaffinity similar to that of p107; however, phosphor-
ylation results in no additional increase in affinity
(LIN5212–34;S20C;phosS28; Kd = 0.3 μM±0.1 μM). This result
corroborates the lack of a phosphate-binding pocket in
Rb. We also mutated the residues in p107ΔL that con-
tact LIN52 phosS28 in the crystal structure such that
they resemble the Rb sequence (R869K, S876Q, Y879F,
and R880K). LIN52 and LIN5212–34;S20C bind the Rb-
like mutant (p107mutant) with weaker affinity compared
with p107ΔL, and phosphorylation does not enhance
affinity (Fig. 3B). The E721–29 peptide binds p107mutant
and p107ΔL with similar affinities, which is consistent
with a lack of interaction between E7 and the phosphate
pocket.
The fact that LIN5212–34 and LIN5212–34;phosS28 bind
p107mutant with greater affinity than Rb suggests that
p107-specific interactions other than the phosphate-
binding pocket stabilize LIN52 association. One possible
explanation observed in the crystal structure is the pres-
ence of I850 in p107. I850 contacts Y849 and stabilizes
the Y849 position for hydrogen bonding to S20 in LIN52
Figure 3. Role of the LxSxExL motif and S28
phosphorylation on LIN52–p107/p130 as-
sociation. (A) Alignment of LIN52 (left) and
pocket protein (right) sequences. The LIN52
LxSxExLxxxpS motif and S28 phosphate-bind-
ing residues are highlighted. (B) Isothermal
titration calorimetry (ITC) affinity measure-
ments of LIN5212–34 variants and E721–29 bind-
ing to pocket proteins. (∗) Value previously
reported (Lee et al. 1998). (C ) T98G cells were
cotransfectedwith LIN52-V5 and the indicated
HA-p130, extracts were immunoprecipitated
with an anti-V5 antibody, and proteinswere de-
tected with the appropriate antibodies in a
Western blot. The band in the LIN9 blot
marked with an asterisk is nonspecific. (D)
T98G cells stably expressing the wild-type
(wt) or mutant LIN52-Flag-HA alleles were se-
rum-starved for 48 h, and the coimmunopreci-
pitation was performed as in C except with an
anti-Flag antibody. (E) As in C, wild-type (wt)
andS20Cmutant LIN52-Flag-HAandviral pro-
teins SV40 large T antigen (LT) and adenovirus
E1A were transiently expressed in cycling
T98G cells as indicated. Band intensities for
the immunoprecipitated HA-LIN52 and p130
were quantified, and the p130/LIN52 ratio is
plotted. Error bars are standard deviations for
two different replicates of the experiment.
Table 2. Affinity of LIN52 peptides for the p107 pocket domain
(see Supplemental Fig. 5 for exemplary ITC traces)
Peptide p107ΔL affinity
LIN5212–34;phosS28 1.4 µM± 0.8 µM
LIN5212–34;L18A;phosS28 14.9 µM± 0.1 µM
LIN5212–34;L24A;phosS28 7.4 µM± 0.9 µM
LIN5212–34;E22A;phosS28 5.5 µM± 0.3 µM
LIN5212–34;+A28;phosS29 1.7 µM± 0.3 µM
LIN5212–34;−A27;phosS27 0.126 µM± 0.002 µM
LIN5212–34;P29A;phosS28 0.035 µM± 0.003 µM
Guiley et al.
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(Fig. 2). In contrast, G710 at the corresponding position in
Rb cannot play the same stabilizing role and is likely a
source of the lower Rb affinity for the noncanonical
LxSxExL motif relative to p107/p130.
We tested the significance of the p107/p130-specific
phosS28-binding site for DREAM assembly in cells (Fig.
3C). T98G cells were cotransfected with V5-tagged
LIN52 and either wild-type HA-p130 or HA-p130 with a
Y928F mutation (equivalent to Y879F in p107). LIN52-
V5 was precipitated with an anti-V5 antibody, and we ex-
amined the amount of precipitated p130 by Western blot.
LIN52 coprecipitated less Y928F mutant p130 protein
than wild-type, supporting the requirement of an intact
phosphate-binding pocket as observed in the crystal struc-
ture for DREAM assembly.
The LxSxExL sequence motif is critical for
DREAM assembly
To explore further the important elements of the LIN52
LxSxExL-bindingmotif, wemeasured the affinity of differ-
ent LIN5212–34 peptides for the p107 pocket domain using
the ITC assay (Table 2; Supplemental Fig. 5). Both the
L18A (Kd = 14.9 μM±0.1 μM) and L24A (Kd = 7.4 μM±
0.9 μM) consensusmutations in LIN52 reduce affinity. Al-
though E22 in LIN52 does notmake any interactions with
p107 in the crystal structure (Fig. 2), we also found that an
E22A mutation (Kd = 5.5 μM±0.1 μM) reduces affinity
fourfold compared with wild type (Kd = 1.4 μM±0.8 μM).
We suggest that, in solution, there is an additional alter-
nate conformation in equilibrium that resembles the E7
peptide conformation but is less stable because of the bur-
ied S20 hydroxyl group.
We also measured the effects of moving the position of
phosS28 relative to the LxSxExL motif. Addition of an al-
anine to the intervening three residues results in similar
affinities (LIN5212–34;+A28;phosS29; Kd = 1.7 μM±0.3 μM),
while the peptide with A27 deleted binds with 10-fold
tighter affinity (LIN5212–34;−A27;phosS27; Kd = 0.126 μM±
0.002 μM). This observation is consistent with a lack of in-
teractions between the intervening sequence and pocket
domain (Fig. 2). The tighter affinity of the shorter se-
quence may result from a reduced entropic penalty for
binding. Many kinases phosphorylate substrates bearing
an (S/T)P motif, which include DYRK1A and the CDKs
(Ubersax and Ferrell 2007). We tested a LIN52 phosS28
P29A mutant to determine whether p107 binding is also
dependent on this motif. The mutant has a higher affinity
(LIN5212–34;P29A;phosS28; Kd = 0.035 μM±0.003 μM) than
wild-type, suggesting that the proline is required for ki-
nase recognition of S28 but is not preferred at this position
for pocket binding.
To determinewhether the p130 pocket associationwith
the LIN52 LxSxExL motif is required for DREAM assem-
bly in cells, we generated LIN52-HA-Flag mutants stably
expressed in T98G cells. We then immunoprecipitated
the Flag sequence and examined the coprecipitation of
p130 by Western blot. When either E22 or S28 is mutated
in LIN52, p130 binding is diminished, while binding of the
MuvB proteins LIN37 and LIN9 is preserved (Fig. 3D). We
also tested the stabilizing effect of an S20Cmutant on the
LIN52–p130 complex by coprecipitation (Fig. 3E). The
LIN52-HA-Flag S20C mutant expresses at a higher level
than wild type but does not coprecipitate a relatively
greater amount of p130. However, when coexpressed
with either E1A or large T-antigen viral proteins, both of
which contain LxCxExφ sequences, LIN52 S20C does
coprecipitate a relatively greater amount of p130 than
wild type. We conclude that the wild-type sequence is
sufficient to coprecipitate p130, but, when challenged
with high-affinity viral proteins, the increase in affinity
from the S20C mutation allows LIN52 to better compete
with E1A and large T-antigen for p130 binding. This result
emphasizes how the weaker LxSxExL motif in LIN52,
even with the addition of S28 phosphorylation, enables
DREAM disassembly by competitor viral oncoproteins.
B-Myb requires LIN52 to bind to MuvB
but does not compete with p130
We next investigated the determinants of B-Myb binding
to MuvB in order to compare the mechanisms of DREAM
and MMB assembly. The evolutionarily conserved MuvB
proteins in the Drosophila melanogaster DREAM com-
plex were found to interact with the C terminus of B-
Myb (Andrejka et al. 2011). To test whether this associa-
tion is direct and conserved in the human proteins, we
performed a series of precipitation experiments with
recombinant B-Myb and MuvB proteins from Sf9 cells
(Fig. 4). We reconstituted the core MuvB subcomplex by
coexpressing GST-LIN994–542, which lacks its poorly con-
served and putative unstructured N terminus, along with
full-lengthGST-LIN37, Strep-RBAP48, andGST-LIN52 as
indicated. The purified complexes were then coprecipi-
tated in the presence of the C terminus of B-Myb (GST-
B-Myb654–700). We found that GST-B-Myb654–700 binds
the MuvB subcomplex only in the presence of LIN52
(Fig. 4A). However, full-length GST-LIN52-HIS, which
is sufficient to coprecipitate p130 (Fig. 1A), is not suffi-
cient to coprecipitate GST-B-Myb654–700 (Fig. 4B).We con-
clude that LIN52 is necessary but not sufficient for B-Myb
binding. The requirement for LIN52 could result from
direct B-Myb–LIN52 contacts or because LIN52 is neces-
sary for a properly structured MuvB core.
We next tested whether p130 and B-Myb compete for
access to MuvB or can both bind simultaneously. We
found that Strep-tagged RbAP48 together with the other
components of the MuvB subcomplex coprecipitate
both GST-B-Myb654–700 and p130 pocket when all compo-
nents are mixed in the same solution (Fig. 4C). Increasing
the amount of p130 does not change the amount of
GST-B-Myb654–700 that coprecipitates, consistent with a
lack of competition (Fig. 4C). We also found that GST-B-
Myb654–700 coprecipitates the p130 pocket if and only if
the components of MuvB are present, demonstrating the
presence of a complex that contains B-Myb654–700, the
p130 pocket, and MuvB all together (Fig. 4D). Based on
these observations that p130 and B-Myb can simultane-
ouslybindMuvBandthat theyhavedifferent requirements
for binding, we conclude that they have nonoverlapping
DREAM assembly and regulation
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binding sites on the MuvB core. In order to demonstrate
that full-length p130 and B-Myb associate together with
MuvB in cells, we precipitated HA-Flag-B-Myb that is sta-
bly expressed in BJ-hTERT fibroblasts (Fig. 4E). We ob-
served coprecipitation of endogenous LIN37 and p130
under conditions that support DREAM assembly, in-
cluding serum starvation and Cdk4/6 inhibition with pal-
bociclib (PD-0332991, Pfizer, Inc.). Although we cannot
rule out a direct association between full-length p130
and B-Myb in this experiment, the data are consistent
with B-Myb coprecipitating p130 through a common
MuvB core.
Figure 4. B-Myb and p130 bind distinct surfaces of MuvB. Coprecipitation experiments were conducted with recombinant proteins
as in Figure 1. (A) Streptactin coprecipitation of Strep-tagged RbAP48, GST-LIN994–542, and GST-LIN37 with GST-B-Myb654–700 in
the absence and presence of GST-LIN52 demonstrates the requirement of LIN52 for B-Myb–MuvB binding. The bandmarked with an as-
terisk is a GST-LIN994–542 degradation product. (B) Ni2+-NTA fails to coprecipitate GST-B-Myb654–700 with GST-LIN52-HIS alone.
(C ) Streptactin coprecipitation of Strep-taggedRbAP48,GST-LIN994–542, GST-LIN37, andGST-LIN52withGST-B-Myb654–700 in the pres-
ence of increasing amounts of p130ΔL. The amount of coprecipitated GST-B-Myb654–700 does not change, demonstrating that the
p130 pocket domain does not compete with B-Myb for MuvB binding. The band marked with an asterisk is a GST-LIN994–542 degrada-
tion product. (D) GST-B-Myb654–700 coprecipitates the untagged p130 pocket domain only in the presence of the untagged MuvB compo-
nents, indicating that both B-Myb and p130 can simultaneously bind MuvB. The bands marked with an asterisk show
degradation products of GST-B-Myb654–700. (E) Association of p130 and MuvB with ectopically expressed B-Myb. BJ-hTERT fibroblasts
stably expressing HA-Flag-tagged GFP (control) or B-Myb were incubated for 24 h in complete medium, in the medium without FBS,
or in medium containing CDK4/6 inhibitor. Proteins of interest were detected by Western blot in the cell extracts (Inputs) and in the
anti-Flag pull-downs (IP:Flag).
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CDK phosphorylation promotes DREAM
disassembly
Components of the MuvB complex fail to associate with
p107 and p130 in cycling cells; however, the mechanism
of DREAM inhibition upon exit from quiescence has not
been elucidated. Considering that LIN52 is found phos-
phorylated and unphosphorylated at S28 when bound to
B-Myb during S phase (Litovchick et al. 2011), dephos-
phorylation of LIN52 S28 is unlikely the primary mecha-
nism promoting DREAM disassembly. Our result that B-
Myb and p130 bind MuvB simultaneously also argues
against a competitive mechanism for DREAM disassem-
bly by which, upon expression, B-Myb displaces p130
from MuvB. Noting the coincident timing of Cdk activa-
tion and DREAM disassembly (Pilkinton et al. 2007), we
tested directly whether Cdk activity correlated with
p130 binding to MuvB. We found that the MuvB com-
ponent LIN37 can coprecipitate a greater amount of
p130 from the extracts of cycling T98G cells in the pres-
ence of the Cdk4/6 inhibitor (Fig. 5A). To observe the
effect of Cdk inhibition on DREAM disassembly upon
cell cycle entry, we released T98G cells from serum
starvation and found that LIN37 coprecipitation of p130
persists to a greater extent in the presence of the Cdk4/6
inhibitor (Fig. 5B). In the absence of inhibitor, the loss
of p130 coprecipitation, beginning at 10 h, correlates
with the disappearance of the hypophosphorylated p130
form (the lower band in the gel). These results demon-
strate that Cdk activity in cells inhibits p130–MuvB
association.
We asked whether Cyclin D1 could inhibit DREAM as-
sembly by directly competing with the LIN52 interaction
at the p130 LxCxE cleft. Cyclin D1 was previously pro-
posed to bind the LxCxE cleft in the Rb pocket domain
(Dowdy et al. 1993). However, we found in our FP assay
(Fig. 1F) that a Cyclin D1 peptide does not displace
LIN52 form p130ΔL. We also titrated the Cyclin D1 pep-
tide bearing its LxCxExE motif into p107ΔL and p130ΔL
in the ITC assay and found no observable binding (Sup-
plemental Fig. 5), suggesting that the Cyclin D1 sequence
does not directly associate with the pocket domain. These
results are supported by our ITC data and previous re-
ports (Singh et al. 2005) that a hydrophobic residue is
necessary at the downstream glutamic acid position in
Cyclin D1.
We hypothesized that Cdk phosphorylation of p130/
p107 inhibits the LIN52 interaction with the p130/p107
pocket domain. In support of this mechanism, we found
that λ phosphatase treatment of the partially phosphory-
lated p130 purified from Sf9 cells increased LIN52–p130
complex stability in a qualitative coprecipitation assay
(Fig. 1A).We quantified the effect of p130 phosphorylation
on LIN52 binding using the FP assay described in Figure
1E. The TMR-LIN5212–34;phosS28 peptide was mixed with
increasing amounts of GST-p130 purified from Sf9 cells
without treatment, with phosphatase treatment, and
with kinase treatment. While phosphatase treatment in-
creases the affinity 3.5-fold, Cdk2 phosphorylation de-
creases the affinity nearly twofold, demonstrating that
p130 phosphorylation weakens LIN52 binding (Fig. 5C).
The observation of a change in affinity upon treatment
with either enzyme reflects the partial phosphorylation
of GST-p130 purified from Sf9 cells.
Our structural observation that phosphorylated LIN52
binds p107/p130 at the LxCxE cleft suggests that Cdk
phosphorylation events resulting in occlusion of the
LxCxE-site would inhibit DREAM assembly. Studies of
inactive Rb have revealed phosphorylation-induced struc-
tural changes that block the LxCxE cleft (Rubin et al.
2005; Burke et al. 2012; Rubin 2013). We considered one
mechanism in which phosphorylation of conserved sites
in the linker between the N-terminal (RbN) and pocket
domains results in RbN–pocket docking (Burke et al.
2012). Alignment of the phosphorylated Rb structure
with the p107–LIN52 complex suggests that an analogous
closed conformation in p107/p130 would inhibit LIN52
binding (Fig. 5D). In the Rb structure, residues in RbN
form hydrogen bonds and salt bridge interactions with
Rb pocket residues; the homologous residues in the
p107 pocket domain contact the LIN52 S28 phosphate
in the structure presented here.
To determine whether CDK phosphorylation disrupts
the DREAM complex through phosphorylation of sites
in the putative p107/p130 interdomain linker, we exam-
ined the effect of p130 T401A and T417A mutation on
MuvB binding in cycling U2OS cells. We expressed
LIN52 together with p130 wild type and the phosphosite
mutant and found that LIN52 coprecipitates a greater
amount of the T401A/T417A double mutant (Fig. 5E).
We also found that the p130 double mutant can coprecipi-
tate a greater amount of endogenous LIN37 thanwild type
(Fig. 5F). In order to test the functional consequences of
mutating Cdk sites, we transfected U2OS cells with
wild-type p130 and the T401A/T417A phosphosite mu-
tant and examined proliferation of cells using S-phase-spe-
cific Ki-67 staining similar to as previously described
(Canhoto et al. 2000). We found that the T401A/T417A
mutant induces a more potent growth arrest than wild
type,which is consistentwith stabilization of theDREAM
complex (Fig. 5G). T401 and T417 phosphorylation have
also been shown to be relevant for regulation of E2F4 activ-
ity (Farkas et al. 2002).Mutation of these sitesmay also in-
fluence p130–E2F4 affinity and contribute to the observed
growth arrest by stabilizing E2F binding.
Discussion
Our structural and binding data support a model in which
the DREAM complex is mediated by the direct associa-
tion of LIN52with the p107/p130 pocket (Fig. 5H). Assem-
bly is promoted by DYRK1A phosphorylation of S28 in
LIN52, while disassembly is induced byCdk phosphoryla-
tion of sites in p107/p130 that promote structural changes
toocclude theLIN52-binding surface. B-Mybbinding is de-
pendent on LIN52 and other members of the MuvB core
and can occur simultaneously with p107/p130 binding in
our assays with recombinant protein and in cells under
conditions in which B-Myb is ectopically expressed and
DREAM assembly and regulation
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p130 is known to be hypophosphorylated. The fact that B-
Mybandp130arenot found together in complexespurified
from mammalian cells is likely due to the coincidence of
B-Myb expression and p130 phosphorylation in those cells
(Litovchick et al. 2007). Complexes were purified from
Drosophila cells containing both Myb and Rbf and may
point to a distinctmechanismof regulation in lowermeta-
zoans. The D. melanogaster Rbf sequences notably lack
Figure 5. p130 phosphorylation weakens LIN52 binding and DREAM activity. (A) T98G cells were incubated for 24 h in the presence or
absence of theCDK4/6 inhibitor palbociclib. Binding of p130 to LIN37was determined by coimmunoprecipitationwith an anti-LIN37 an-
tibody and detection of proteins in aWestern blot. The bandmarkedwith an asterisk in the p130 input blot is a nonspecific band. (B) T98G
cellswere serum-starved for 72h and then releasedwith additionof 10%FBS in the absenceor presence of theCdk4/6 inhibitor palbociclib.
After harvesting cells at the indicated time points, extracts were immunoprecipitated with an anti-LIN37 antibody and probed for LIN37
and p130. The bandmarked with an asterisk in the p130 input blot is a nonspecific band. (C ) FP binding assay of TMR-labeled LIN5212–34;
phosS28 to GST-p130. The GST-p130 was purified from sf9 cells and used untreated (green line, circles), treated with λ phosphatase (yellow
line, squares), and treatedwithCdk2kinase (blue line, triangles). PurifiedGSTalonewas used as a negative control (inverted triangles). The
expected effect of enzyme treatment was corroborated with a Phos-tag gel (Supplemental Fig. 1C). (D) Overlay of the LIN5212–34;phosS28–
p107 structure and phosphorylated Rb55–787 structure (PDB: 4ELJ). Residues in p107 that bind the S28 phosphate in LIN52 (rendered as
transparent blue sticks) are analogous to residues in the Rb pocket domain that bind the docked RbN domain (pink) when Rb is phosphor-
ylated. (E) U2-OS cells were transfected with LIN52-V5 and the wild-type or T401A/T417A (TTAA) mutant HA-p130. Extracts were im-
munoprecipitated with anti-V5 antibody, and the indicated proteins were detected by Western blot. (F ) Same as in E except an anti-HA
antibody was used for immunoprecipitation. (G) U2OS cells were cotransfected with wild-type or the T410A/T417A (TTAA) mutant of
p130 and GFP as tracer. The expression of Ki-67 was determined by indirect immunofluorescence cell staining at 48 h after transfection.
The graph shows the average values and standard deviations (error bars) of three replicate experiments in which at least 100 cells were
counted per condition. The P-value evaluating statistical significance was calculated using a two-tailed Student’s t-test. (H) Model for
DREAM complex disassembly and MMB complex assembly upon Cdk activation.
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conserved phosphorylation sites equivalent to T401 and
T417 in p130, which further points to their importance
in disassociating p130 fromMuvB.
LIN52 accesses the LxCxE cleft of the pocket domain
using a noncanonical and nonoptimal LxSxExL motif in
combination with phosphorylation at S28. The weak af-
finity of the LxSxExL sequence sensitizes the association
to regulatory phosphorylation by DYRK1A. Kinase phos-
phorylation acts as a switch because it increases LIN52
binding to submicromolar affinity. We note that in con-
trast to higher orthologs, Caenorhabditis elegans LIN52
maintains the canonical, tight-binding LxCxE motif and
lacks the equivalent DYRK1A consensus surrounding
the S28 residue. We predict that DREAM in C. elegans
is not regulated equivalently by phosphorylation, and
LIN52 and LIN35 constitutively form a stable complex.
The LIN52 sequence in D. melanogaster resembles our
LIN5212–34;ΔA27;phosS27 peptide, suggesting that Droso-
phila Rbf proteins and LIN52 also form a highly stable,
phosphorylation-dependent interaction.
The requirement for LIN52 phosphorylation is an im-
portant source of specificity for p107 and p130 in DREAM
assembly. Unlike Rb, the p107 and p130 pocket domains
contain the proper phosphate-binding site. Phylogenetic
sequence analysis of pocket proteins suggests that Rb ap-
pears more recently than p107 and p130, which are closer
in sequence to pocket proteins such as LIN35 and Rbf in
lower metazoans (van den Heuvel and Dyson 2008; Sada-
sivam and DeCaprio 2013). It is not clear then why Rb
evolved such that it does not bind MuvB, although one
possibility is that the LxCxE cleft in Rb must be reserved
for some alternate unique function.
Despite their diverse cellular roles, the universal bio-
chemical function of pocket proteins is to assemble pro-
tein complexes (Cobrinik 2005; Dick and Rubin 2013). It
is estimated that several hundred proteins interact with
Rb and its pocket protein paralogs, and the LxCxE cleft
has been described as the key interface for these complex-
es (Morris and Dyson 2001). The crystal structure present-
ed here of the p107–LIN52 complex provides the first
structural insights into how cellular proteins contact the
cleft. It implicates the LxSxExLxxxpS sequence as a novel
binding motif that can be regulated by phosphorylation.
We searched the Scansite 3 server (Obenauer et al. 2003)
to identify other potential p107/p130-binding partners
that use thismotif and themotifs identified in our binding
studies that bind the novel phosphate-binding pocket. We
identified 203 proteins that matched our motifs, although
only 13 are known to be phosphorylated on the consensus
serine (Supplemental Table 1).
Cdk phosphorylation has been well characterized as a
mechanism for inactivating pocket proteins, and both
structural and functional studies have implicated the ef-
fects of phosphorylation on inhibiting pocket protein in-
teractions (Cobrinik 2005; Rubin 2013). Our results here
further support phosphorylation of p107/p130 as a mech-
anism of inactivating the DREAM complex by dissociat-
ing pocket proteins from the MuvB core. Mutation of
conserved Cdk sites T401 and T417 enhances the growth
arrest properties of p130 and stabilizes the DREAM com-
plex (Fig. 5). Structural and sequence comparisons be-
tween p107/p130 and Rb suggest that a conserved closed
conformation that occludes the LxCxE cleft is induced
by phosphorylation. We note that additional Cdk sites
in p107/p130 may contribute to inhibition of LIN52 bind-
ing and that phosphorylation may also contribute to
DREAM dissociation by inhibiting p107/p130 association
with E2F proteins.
It has been suspected that cancer cells can in certain
contexts avert the effect of cytotoxic treatments by enter-
ing quiescence. As an important mediator of cell cycle
exit, DREAM may be an important additional target
during chemotherapy. For example, cells from gastroin-
testinal stromal tumors enter quiescence following treat-
ment with imatinib, and inhibition of DREAM assembly
through genetic knockdown alternatively induces apo-
ptosis (Boichuk et al. 2013). Our structural characteriza-
tion of LIN52 association with p107 suggests that
inhibitors of protein interactions at the LxCxE cleft in
pocket proteins would likely block DREAM function in
vivo. It is encouraging that only a short peptide corre-
sponding to the E7 sequence is sufficient for inhibition
of LIN52 association in vitro (Fig. 1F), and small molecule
inhibitors of the E7 LxCxE–Rb interaction have been re-
ported (Fera et al. 2012). Discovery of more potent chem-
ical inhibitors of LxCxE–pocket bindingmay prove to be a
viable strategy for preventing cancer cells from escaping
to quiescence as a mechanism for surviving therapeutic
treatment.
Materials and methods
Protein expression and peptides
A human Rb pocket with its loop deleted (residues N380–G581;
K643–R787), a p107 pocket (T391–Q972), p107ΔL (T391–T599;
N780–I887; K924–Q972), and p130 ΔL (H424–D632; N828–
K935; E999–Q1049) were expressed and purified from E. coli
BL21 cells as GST fusion proteins. Cells were induced with 1
mM IPTG and grown overnight at 20°C. Lysates were first puri-
fied by GS4B affinity chromatography. The elution fraction was
then subjected to TEV protease cleavage and dialyzed overnight
in 25 mM Tris, 200 mM NaCl, 1 mM DTT, and 0.5 mM EDTA
(pH 8.0). The protein was then passed over GS4B affinity resin
again to remove free GST, concentrated, and stored in a buffer
containing 20 mM Tris, 200 mM NaCl, 1 mM DTT, and 20%
glycerol (pH 8.0).
LIN52, LIN37, RBBP48, LIN9, B-Myb, and full-length p130
were expressed and purified from Sf9 cells (Expression Systems)
using baculovirus vectors. Proteins were purified as described
above, and the GST-free samples were passed over a Superdex-
200 column that was equilibrated in the dialysis buffer following
TEV cleavage. p130 was phosphatase-treated with 1% λ phospha-
tase by mass using the manufacturer’s protocol (New England
Biolabs). Cdk2 treatment was performed as described (Burke
et al. 2010) except the Cdk2 activator Speedy was used instead
of a cyclin activator. Following treatment, GST-p130was separat-
ed from the enzymes using a Superdex-200 column.
The LIN5212–34;phosS28 and E721–29 peptides used for crystalliza-
tion were synthesized by BioPeptide LLC. The LIN5212–34;P29A;
phosS28 peptide and all other peptides used for ITCand the FP assay
were synthesized by GenScript, Inc.
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Crystallization, data collection, structure determination,
and model refinement
p107ΔL was prepared for crystallization by elution from a Super-
dex-75 (GE Healthcare) column in a buffer containing 25 mM
Tris, 500 mMNaCl, and 5 mM DTT (pH 8.0). LIN5212 –34;phosS28
was added in threefold molar excess to 14 mg/mL p107ΔL, and
E7
21–29
was added in twofold molar excess to 12 mg/mL p107ΔL.
After incubation for 30 min on ice, both complexes were crystal-
lized by sitting-drop vapor diffusion at 4°C. Plates formed after 2
wk in 100 mMMES (pH 6.5), 1.6 M (NH4)2SO4, and 4% PEG 400
for the LIN5212–34;phosS28 complex and in 100 mM HEPES (pH
7.5), 1.7 M (NH4)2SO4, and 4% PEG 400 for the E7
21–29 complex.
Crystals were frozen in the proper well buffer with 20% ethylene
glycol. Some crystals containing the LIN5212–34;phosS28 peptide
were soaked with 20-fold molar excess of the P29A mutant pep-
tide before freezing.
Data were collected at the Advanced Photon Source, Argonne
National Laboratory at Beamline 23-IDB. Diffraction spots were
integrated using MOSFLM (Leslie 2006), and data were merged
and scaled using Scala (Bailey 1994). Phases were first solved
for the E721–29 complex by molecular replacement using Phaser
(Mccoy et al. 2007). A homology model of p107ΔL, which was
constructed using the Rb pocket domain (PDB: 3POM), was
used as a search model. p107ΔL complexes with LIN52 peptides
were then solved using the E7–p107 complex as a search model,
as the crystal form was slightly different. Peptides were built
with Coot (Emsley and Cowtan 2004), and the models were
refined with PHENIX (Adams et al. 2010). Coordinates and
structure factors have been deposited in PDB for the structures
with the E721–29, LIN5212–34;phosS28, and LIN5212–34;P29A;phosS28
peptides under accession codes 4YOZ, 4YOS, and 4YOO,
respectively.
Coprecipitation assays
For assays with recombinant protein, 50 μg of each indicated pro-
tein was incubated with 15 μL of either GS4B resin, Streptactin
resin, or nickel sepharose Excel resin (all from GE Healthcare)
in a buffer containing 25 mM Tris, 150 mM NaCl, and 1 mM
DTT (pH 8.0) for 30min on ice. The resin waswashed three times
using the same buffer or with the addition of 20 mM imidazole
and was eluted using 30 μL of elution buffer containing 25 mM
Tris, 200 mM NaCl, and 1 mM DTT (pH 8.0) with either 20
mM glutathione, 400 mM imidazole, or 10 mM desthiobiotin
as needed. Under these conditions, we did not find that GST
dimerization influences our results. For example, in Figure 4A
GST-B-Myb654 –700 only coprecipitates with other GST-tagged
components of the MuvB core when LIN52 is present. Samples
were analyzed by SDS-PAGE with Coomassie staining.
For assays in cells, stable cell lines were generated using a
pMSCV-Flag-HA retroviral vector as described (Litovchick et al.
2007). Alternatively, cells were transiently transfected with
pcDNA3.1 vectors encoding HA-tagged wild-type or mutant
p130 alleles or pBabe vectors encoding SV40 large T antigen or ad-
enovirus E1A. Mutant LIN52 and p130 alleles were obtained us-
ing site-directed mutagenesis (QuikChange, Agilent). T98G and
BJ-hTERT cells were chosen for assaying DREAM assembly
because they have intact Rb family genes and significant G1 pop-
ulations in asynchronously growing cells and arrest in G0/G1
readily (Litovchick et al. 2007). U2OS cells are highly prolifera-
tive and sensitive to overexpression of Rb family proteins; there-
fore, they were used for characterizing p130 phosphorylation site
mutants as described (Farkas et al. 2002). Cells were extracted us-
ing EBC lysis buffer (50 mM Tris, 150 mMNaCl, 0.5% NP-40 at
pH 7.4), immunoprecipitated, and subjected toWestern blot anal-
ysis as described previously (Litovchick et al. 2007). Band intensi-
ties were quantified using ImageJ software.
Proliferation assay
U2OS cells were seeded onto six-well plates at 2 × 105 cells per
well and transfected with pcDNA3.1 vectors encoding p130 con-
structs and GFP. The p130 vector was transfected at a 4:1 molar
ratio relative to the GFP vector. Forty-eight hours after transfec-
tion, cells were trypsinized and seeded in triplicate onto six-
well plates containing glass coverslips and allowed to attach for
24 h. Proliferating GFP-positive and GFP-negative cells were de-
tected by indirect immunofluorescence staining using anti-Ki67
(Millipore) antibodies as described in Canhoto et al. (2000). To
determine the fraction of proliferating cells in each sample, the
number of Ki67-positive cells was determined in at least 100 cells
per condition using an EVOS fluorescent microscope (AMG ad-
vanced microscope group) and a 20× objective. U2OS cells were
chosen for this assay because they have intact Rb family mem-
bers and are highly proliferative and thus sensitive to increases
in the DREAM arrest activity.
Calorimetry
Equilibrium dissociation constants for p107, p130, Rb, LIN52,
and E7 binding were obtained using ITC with the Micro Cal
VP-ITC system (GE Healthcare). Peptides and proteins were dia-
lyzed overnight and titrated into a buffer containing 25 mM
Tris, 200 mM NaCl, and 5 mM BME (pH 8.0) at 15°C. Because
of the difficulty in accurately determining peptide concentration,
the peptide concentration was adjusted in the fitting such that all
of the stoichiometry values were equal to 1.0.
FP assay
TMR-LIN5212–34;phosS28 was mixed at 20 nM with p130ΔL GST-
p130 in a buffer containing 40 mM Tris, 150 mM NaCl, 1 mM
DTT, and 0.1% Tween (pH 8.0). Twenty microliters of the reac-
tion was used for the measurement in a 384-well plate. FP mea-
surements were made in triplicate using a Perkin-Elmer
EnVision plate reader, and reported FP values were determined
using instrument software. Error bars in the plots show standard
deviations for the threemeasurements of each point, while the re-
ported errors in Kd and KI are errors derived from curve fits. We
note that absolute Kd measurements were typically tighter using
the FP assay compared with ITC and suggest that this difference
may be due to the presence of the dye in the peptide or other
subtle differences in experimental conditions.
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